Business context and reporting period
GeneDx Holdings Corp. filed this unaudited Form 10-Q for the three months ended March 31, 2024. The company provides genomics-related diagnostic and information services, with a strategic focus on pediatric and rare-disease testing, including whole exome and genome sequencing. Its Legacy Sema4 reproductive, women’s health and somatic oncology diagnostics business has been shut down.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Revenue | $62.4 million | $43.1 million |
| Gross profit | $37.4 million | $15.2 million |
| GAAP gross margin | 59.9% | 35.3% |
| Adjusted gross margin (non-GAAP) | 61.4% | 33.0% |
| Operating loss | $13.7 million | $60.4 million |
| Net loss | $20.2 million | $61.0 million |
| Net cash used in operating activities | $16.4 million | $55.6 million |
Diagnostic test revenue was $61.1 million, up 46%; other revenue was $1.3 million. Basic and diluted loss per share was $0.78, compared with $3.04. The company reported 55,223 resulted tests versus approximately 52,778; whole exome and genome sequencing test volumes increased 91% year over year.
At March 31, cash and cash equivalents were $83.7 million and marketable securities were $29.2 million, totaling approximately $112.9 million. Cash, cash equivalents and restricted cash totaled $84.7 million. Total debt principal was $56.3 million; long-term debt, net of current portion and issuance costs, was $52.3 million. Current assets were $163.4 million and current liabilities were $50.7 million.
Investing activities provided $0.8 million, principally reflecting marketable-security sales and maturities net of purchases. Financing activities used $0.4 million, mainly for finance-lease payments. The company had a $50 million Perceptive term loan funded, with a further $25 million tranche subject to conditions, including a revenue milestone. The facility bears interest at Term SOFR plus 7.5%, is secured by substantially all assets, and matures in October 2028.
Material changes versus the prior comparable period
- Revenue rose 45%, primarily from GeneDx testing. Management attributed the increase mainly to 96% growth in whole exome and genome sequencing revenue, driven by higher volume, partly offset by declines in other tests and the discontinued business.
- Gross profit increased $22.2 million. Management cited a more favorable test mix, improved exome reimbursement, cost-per-test leverage and the removal of discontinued-business costs.
- Operating loss narrowed substantially, with general and administrative expense down 49% to $22.4 million and research and development expense down 21% to $11.6 million. Selling and marketing expense rose 20% to $16.1 million to support commercial growth.
- Net loss improvement was partly offset by a $6.1 million non-cash loss from changes in fair value of warrants and contingent liabilities. Prior-year other income included $2.8 million of DECD loan forgiveness.
- Operating cash use decreased by $39.1 million year over year. The prior-year financing inflow included $135.4 million of net proceeds from equity offerings.
Outlook, commentary, risks and unusual items
- Management said cash, cash equivalents and available-for-sale marketable securities are sufficient to fund operations for at least 12 months from the filing date. It also noted possible future financing, including the conditional $25 million loan tranche or equity and other debt funding.
- Cost-saving initiatives, including workforce reductions, are expected to produce more than $40 million in annual cost reductions. The disclosed reductions affected approximately 85 positions and reduced the workforce by 10% from its size at the time of the August 2023 action. Remaining cash severance payments were expected to be completed in less than one year.
- A $42 million settlement with a third-party payor is payable in installments through June 30, 2026; recorded related liabilities were $23.9 million at quarter-end. Changes in estimates of variable consideration increased Q1 2024 revenue by a net $5.7 million. Payors may deny or seek recoupment of payments, creating revenue and reserve uncertainty.
- The company reported a material weakness in internal control over financial reporting related to IT access and program-change controls. It said remediation was underway but the weakness was not fully remediated as of March 31, 2024; disclosure controls were therefore not effective. Management nevertheless stated the financial statements were fairly stated in all material respects.
- Risk disclosures include potential future FDA regulation of laboratory-developed tests, reimbursement and billing challenges, privacy and cybersecurity exposure, and changing data-protection rules. The filing notes prior HIPAA security incidents, including some reportable breaches. It also describes pending securities and derivative litigation, which the company believes is without merit.
No specific revenue or earnings guidance was provided in the filing.
Most important facts for investors to verify
- Whether growth in sequencing volume and reimbursement, and the improved gross margin, persist as the business scales.
- Whether cash burn remains consistent with management’s stated liquidity outlook, and whether the conditional Perceptive tranche becomes available.
- Progress and realized savings from restructuring, including any continuing costs of exiting Legacy Sema4.
- Changes in third-party payor reserves, recoupments and payments under the $42 million settlement.
- Remediation and testing of the disclosed material weakness, and developments in FDA, privacy and litigation risks.